Fighting antimicrobial resistance: a new antimicrobial medicinal product marketed in Belgium

date: 20/03/2024

In the fight against antimicrobial resistance, it is important to improve the diversity of therapeutic treatments to enable medical doctors to make the most appropriate choice. Maribavir, a new viral active substance, has recently been launched on the Belgian market.

As part of the fight against antimicrobial resistance (AMR), the FAMHP has developed a Belgian national action plan "One World, One Health", in collaboration with the other Belgian public services involved. This plan is based on the three pillars of health: human health, animal health and the environment. It proposes concrete actions to combat antimicrobial resistance in a comprehensive and coordinated way. The FAMHP's activities are aimed at making new antimicrobials available and keeping older ones accessible. In this context, the FAMHP informs healthcare professionals of the recent placing on the market of one new antimicrobial medicine.

A maribavir-based antiviral film-coated tablet (Livtencity 200 mg) has been on the market since 1 March 2024.
Livtencity is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

More information
•    Package leaflet for Livtencity 200 mg
•    Summary of product characteristics for Livtencity 200 mg 

You can check the availability of all medicinal products (recently) marketed in Belgium via PharmaStatus.

Last updated on 20/03/2024